Signatera™ for early detection of molecular residual disease using ctDNA

Detect residual disease and recurrence early in colorectal cancer (CRC). How often should Signatera be ordered for CRC patients?

CIRCULATE Japan Summary

Circulating tumor DNA (ctDNA) informs clinical practice in patients with recurrent metastatic gastroesophageal cancers

Circulating Tumor DNA as a Marker of Recurrence Risk in Locoregional Esophagogastric Cancers with Pathologic Complete Response

Feasibility and Dynamics of Preoperative Circulating Tumor DNA in Gastroesophageal Cancer Patients Receiving Preoperative Treatment

Molecular Residual Disease and Efficacy of Adjuvant Chemotherapy in Patients with Colorectal Cancer

Analytical validation of the Altera tumor genomic profiling test

Implementation and outcomes of population-based hereditary cancer testing across a diverse multi-location breast imaging center

Cell-free DNA monitoring in a phase II study of adjuvant endocrine therapy with CDK 4/6 inhibitor ribociclib

Monitoring for response and recurrence in neoadjuvant-treated hormone receptor-positive HER2-negative breast cancer

Signatera Knowing early can make a difference

Signatera is a new cancer surveillance test uniquely personalized for each patient.

Compassionate Care Application

Oncology Patient Signatera Requisition Form